2. Search Result
Search Result
Results for "

enteropathogenic

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17624
    Framycetin
    1 Publications Verification

    Neomycin B; Fradiomycin B

    		 Bacterial Antibiotic Infection
    Framycetin (Neomycin B), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections .
    Framycetin
  • HY-17624A
    Framycetin sulfate
    1 Publications Verification

    Neomycin B sulfate; Fradiomycin B sulfate

    		 Antibiotic Bacterial Infection
    Framycetin sulfate (Neomycin B sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin sulfate competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin sulfate inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin sulfate, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections .
    Framycetin sulfate
  • HY-106084
    Cefteram

    T-2525; RO 19-5247; Cefterame

    		 Bacterial Infection
    Cefteram (T-2525) is the free acid of Cefteram pivoxil (HY-106571), which is an orally active cephalosporin ester. Cefteram potently targets to the enteropathogenic Enterobacteriaceae and Vibrionaceae .
    Cefteram
  • HY-17624AR
    Framycetin sulfate (Standard)

    Neomycin B sulfate (Standard); Fradiomycin B sulfate (Standard)

    		 Reference Standards Antibiotic Bacterial Infection
    Framycetin (sulfate) (Standard) is the analytical standard of Framycetin (sulfate). This product is intended for research and analytical applications. Framycetin sulfate (Neomycin B sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin sulfate competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin sulfate inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin sulfate, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections .
    Framycetin sulfate (Standard)
  • HY-B1894
    Cefetamet pivoxyl

    Ro 15-8075 free base

    		 Antibiotic Bacterial Infection
    Cefetamet pivoxyl (Ro 15-8075 free base) is an orally active cephalosporin Antibiotic and a prodrug of Cefetamet (HY-A0111). After ingestion, Cefetamet pivoxyl is hydrolyzed by gastrointestinal esterases to form Cefetamet. Cefetamet pivoxyl is primarily active against aerobic Gram-negative bacteria (such as Enterobacteriaceae, *Neisseria*, *Haemophilus*) and some Gram-positive bacteria (such as non-enterococcal streptococci). Cefetamet pivoxyl exhibits potent in vivo antibacterial activity against strains of Gram-positive bacteria (S. pyogenes) and Gram-negative bacteria (E. coli, K. pneumoniae, S. marcescens, P. vulgaris, P. mirabilis, H. influenzae) .
    Cefetamet pivoxyl
  • HY-147127
    WEN05-03

    		Bacterial ATP Synthase Infection
    WEN05-03 is a EscN ATPase inhibitor. WEN05-03 blocks the active site of EscN ATPase and competitively inhibits its ATP hydrolysis activity. WEN05-03 completely blocks actin cluster formation, reduces actin pedestal formation, and decreases the toxicity of infected mammalian cells. WEN05-03 can be used in studies related to enteropathogenic E. coli (EPEC) infection .
    WEN05-03
  • HY-17624S
    Framycetin-d2

    Neomycin B-d2; Fradiomycin B-d2

    		 Isotope-Labeled Compounds Others
    Framycetin-d2 (Neomycin B-d2) is the deuterium labeled Framycetin (HY-17624). Framycetin (Neomycin B), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections.
    Framycetin-d2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: